These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 37457687)

  • 1. Rapid determination of influenza vaccine potency by an SPR-based method using subtype or lineage-specific monoclonal antibodies.
    Narayan K; Paduraru C; Blake T; Arunachalam AB
    Front Immunol; 2023; 14():1128683. PubMed ID: 37457687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel approach for preparation of the antisera reagent for potency determination of inactivated H7N9 influenza vaccines.
    Schmeisser F; Jing X; Joshi M; Vasudevan A; Soto J; Li X; Choudhary A; Baichoo N; Resnick J; Ye Z; McCormick W; Weir JP
    Influenza Other Respir Viruses; 2016 Mar; 10(2):134-40. PubMed ID: 26616263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of influenza B identity and potency in quadrivalent inactivated influenza vaccines using lineage-specific monoclonal antibodies.
    Verma S; Soto J; Vasudevan A; Schmeisser F; Alvarado-Facundo E; Wang W; Weiss CD; Weir JP
    PLoS One; 2017; 12(4):e0175733. PubMed ID: 28423025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An ELISA-based assay for determining haemagglutinin potency in egg, cell, or recombinant protein derived influenza vaccines.
    Bodle J; Vandenberg K; Laurie K; Barr IG; Zhang Y; Rockman S
    Front Immunol; 2023; 14():1147028. PubMed ID: 37033922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel antibody-independent receptor-binding SPR-based assay for rapid measurement of influenza vaccine potency.
    Khurana S; King LR; Manischewitz J; Coyle EM; Golding H
    Vaccine; 2014 Apr; 32(19):2188-97. PubMed ID: 24613520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inactivated influenza vaccine stress can affect in vitro potency assay relationship to immunogenicity.
    Wen Y; Palladino G; Xie Y; Ferrari A; Settembre EC
    Vaccine; 2018 May; 36(21):3010-3017. PubMed ID: 29680201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A monoclonal antibody-based immunoassay for measuring the potency of 2009 pandemic influenza H1N1 vaccines.
    Schmeisser F; Vasudevan A; Soto J; Kumar A; Williams O; Weir JP
    Influenza Other Respir Viruses; 2014 Sep; 8(5):587-95. PubMed ID: 25087462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of H5N1 vaccine potency using reference antisera from heterologous strains of influenza.
    Vodeiko GM; Weir JP
    Influenza Other Respir Viruses; 2012 May; 6(3):176-87. PubMed ID: 21902817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing the stability-indicating properties of alternative potency assays for inactivated influenza vaccine.
    Ekimov A; Arunachalam AB; Blake T; Bodle J; Couzens L; Dubey S; Eichelberger M; Engelhardt OG; Gubinelli F; Joshi M; Melnyk D; Palladino G; Rigsby P; Rockman S; Savina N; Smith E; Gilchrist SAN;
    Vaccine; 2023 Jul; 41(32):4639-4647. PubMed ID: 37344260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Universal monoclonal antibody-based influenza hemagglutinin quantitative enzyme-linked immunosorbent assay.
    Chae W; Kim P; Hwang BJ; Seong BL
    Vaccine; 2019 Mar; 37(11):1457-1466. PubMed ID: 30765169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potency determination of inactivated H7 influenza vaccines using monoclonal antibody-based ELISA and biolayer interferometry assays.
    Vasudevan A; Woerner A; Schmeisser F; Verma S; Williams O; Weir JP
    Influenza Other Respir Viruses; 2018 Mar; 12(2):250-258. PubMed ID: 29152878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conformationally selective biophysical assay for influenza vaccine potency determination.
    Wen Y; Han L; Palladino G; Ferrari A; Xie Y; Carfi A; Dormitzer PR; Settembre EC
    Vaccine; 2015 Oct; 33(41):5342-5349. PubMed ID: 26348403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An alternative method for preparation of pandemic influenza strain-specific antibody for vaccine potency determination.
    Schmeisser F; Vodeiko GM; Lugovtsev VY; Stout RR; Weir JP
    Vaccine; 2010 Mar; 28(12):2442-9. PubMed ID: 20074687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant HA1 produced in E. coli forms functional oligomers and generates strain-specific SRID potency antibodies for pandemic influenza vaccines.
    Khurana S; Larkin C; Verma S; Joshi MB; Fontana J; Steven AC; King LR; Manischewitz J; McCormick W; Gupta RK; Golding H
    Vaccine; 2011 Aug; 29(34):5657-65. PubMed ID: 21704111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of the potency of a cell-based seasonal quadrivalent influenza vaccine using a purified primary liquid standard.
    Takahashi H; Fujimoto T; Horikoshi F; Uotani T; Okutani M; Shimasaki N; Hamamoto I; Odagiri T; Nobusawa E
    Biologicals; 2020 Nov; 68():32-39. PubMed ID: 33023810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reference antigen-free and antibody-free LTD-IDMS assay for influenza H7N9 vaccine in vitro potency determination.
    Morgenstern K; Xie Y; Palladino G; Barr JR; Settembre EC; Williams TL; Wen Y
    Vaccine; 2018 Oct; 36(41):6144-6151. PubMed ID: 30194004
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    An Y; Parsons LM; Jankowska E; Melnyk D; Joshi M; Cipollo JF
    J Virol; 2019 Jan; 93(2):. PubMed ID: 30355697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemagglutinin Quantitative ELISA-based Potency Assay for Trivalent Seasonal Influenza Vaccine Using Group-Specific Universal Monoclonal Antibodies.
    Chae W; Kim P; Kim H; Cheong YC; Kim YS; Kang SM; Seong BL
    Sci Rep; 2019 Dec; 9(1):19675. PubMed ID: 31873147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The CombE-IDMS Alternate Potency Method for H5N1 and H5N8 Cell-Based Vaccines.
    Donohue MP; Cao Z; Bowen T; Dickinson R; Zhang Y; Qian J
    Vaccines (Basel); 2023 Dec; 11(12):. PubMed ID: 38140203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and fit-for-purpose verification of an LC-MS method for quantitation of hemagglutinin and neuraminidase proteins in influenza virus-like particle vaccine candidates.
    Guo J; Lu Y; Zhang Y; Mugabe S; Wei Z; Borisov OV
    Anal Biochem; 2020 Mar; 592():113577. PubMed ID: 31926146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.